CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Takeda Pharmaceutical Company Limited - 4502 CFD

4790.49
0.76%
Market Trading Hours* (UTC) Opens on Wednesday at 00:00

Mon - Fri: 00:00 - 02:30 03:30 - 06:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 32.92
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.010986 %
Charges from full value of position ($-2.09)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.010986%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.011237 %
Charges from full value of position ($-2.14)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.011237%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency JPY
Margin 5%
Stock exchange Japan
Commission on trade 0%

*Information provided by Capital.com

Takeda Pharmaceutical Co Ltd ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 4754.58
Open* 4772.53
1-Year Change* 26.2%
Day's Range* 4772.53 - 4809.74
52 wk Range 3,663.00-4,645.00
Average Volume (10 days) 3.51M
Average Volume (3 months) 77.55M
Market Cap 7,161.70B
P/E Ratio 23.56
Shares Outstanding 1.55B
Revenue 4,113.63B
EPS 192.12
Dividend (Yield %) 3.97702
Beta 1.00
Next Earnings Date Oct 26, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 26, 2023 4802.56 15.07 0.31% 4787.49 4810.84 4759.56
Sep 25, 2023 4754.58 34.91 0.74% 4719.67 4771.64 4719.67
Sep 22, 2023 4693.74 -18.95 -0.40% 4712.69 4736.03 4682.77
Sep 21, 2023 4739.72 -41.79 -0.87% 4781.51 4788.90 4725.66
Sep 20, 2023 4800.46 -12.57 -0.26% 4813.03 4823.50 4786.49
Sep 19, 2023 4812.43 22.94 0.48% 4789.49 4835.57 4784.39
Sep 15, 2023 4845.34 47.87 1.00% 4797.47 4859.42 4776.52
Sep 14, 2023 4788.49 78.79 1.67% 4709.70 4809.55 4678.16
Sep 13, 2023 4698.72 22.93 0.49% 4675.79 4708.90 4642.87
Sep 12, 2023 4649.95 101.83 2.24% 4548.12 4685.17 4542.14
Sep 11, 2023 4529.17 25.53 0.57% 4503.64 4536.56 4484.29
Sep 8, 2023 4499.35 -34.81 -0.77% 4534.16 4542.73 4497.26
Sep 7, 2023 4516.31 11.07 0.25% 4505.24 4531.47 4497.36
Sep 6, 2023 4510.22 1.99 0.04% 4508.23 4531.57 4502.24
Sep 5, 2023 4530.17 18.95 0.42% 4511.22 4534.26 4505.24
Sep 4, 2023 4520.19 23.83 0.53% 4496.36 4523.69 4473.32
Sep 1, 2023 4495.26 11.97 0.27% 4483.29 4511.32 4476.31
Aug 31, 2023 4489.27 20.94 0.47% 4468.33 4508.53 4462.34
Aug 30, 2023 4474.31 19.94 0.45% 4454.37 4489.38 4443.39
Aug 29, 2023 4457.46 -6.88 -0.15% 4464.34 4478.41 4452.37

Takeda Pharmaceutical Company Limited Events

Time (UTC) Country Event
Thursday, September 28, 2023

Time (UTC)

12:00

Country

JP

Event

Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd

Forecast

-

Previous

-
Thursday, October 26, 2023

Time (UTC)

06:00

Country

JP

Event

Q2 2024 Takeda Pharmaceutical Co Ltd Earnings Release
Q2 2024 Takeda Pharmaceutical Co Ltd Earnings Release

Forecast

-

Previous

-
Wednesday, January 31, 2024

Time (UTC)

06:00

Country

JP

Event

Q3 2024 Takeda Pharmaceutical Co Ltd Earnings Release
Q3 2024 Takeda Pharmaceutical Co Ltd Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total revenue 4027480 3569010 3197810 3291190 2097220
Revenue 4027480 3569010 3197810 3291190 2097220
Cost of Revenue, Total 1244070 1106850 994308 1089760 651729
Gross Profit 2783410 2462160 2203500 2201420 1445500
Total Operating Expense 3494180 3123810 2596860 3193730 1874650
Selling/General/Admin. Expenses, Total 997309 886361 875663 964737 717599
Research & Development 633325 526087 455833 492381 368298
Depreciation / Amortization 542443 472915 421864 455420 178617
Unusual Expense (Income) 21593 100290 -265230 189043 -41201
Other Operating Expenses, Total 55443 31309 114422 2384 -2507
Operating Income 533293 445198 600952 97459 222577
Interest Income (Expense), Net Non-Operating -158203 -142628 -234717 -158213 -94965
Other, Net 1
Net Income Before Taxes 375090 302571 366235 -60754 127612
Net Income After Taxes 317038 230166 376171 44290 135080
Minority Interest -21 -107 -166 -49 112
Net Income Before Extra. Items 317017 230059 376005 44241 135192
Net Income 317017 230059 376005 44241 135192
Income Available to Common Excl. Extra. Items 317017 230059 376005 44241 135192
Income Available to Common Incl. Extra. Items 317017 230059 376005 44241 135192
Diluted Net Income 317017 230059 376005 44241 135192
Diluted Weighted Average Shares 1569.87 1577.17 1573.54 1566.2 966.897
Diluted EPS Excluding Extraordinary Items 201.938 145.868 238.955 28.2473 139.82
Dividends per Share - Common Stock Primary Issue 180 180 180 180 180
Diluted Normalized EPS 213.564 194.24 129.394 106.703 112.123
Interest Expense (Income) - Net Operating 2112
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 1058620 956156 1096550 1002310 972465
Revenue 1058620 956156 1096550 1002310 972465
Cost of Revenue, Total 321114 309772 335973 305445 292882
Gross Profit 737504 646384 760578 696862 679583
Total Operating Expense 890047 867594 949561 897869 821950
Selling/General/Admin. Expenses, Total 248113 254796 262299 248734 231480
Research & Development 162741 160944 174629 154145 143607
Depreciation / Amortization 129423 133224 135576 142366 131277
Unusual Expense (Income) 11243 14898
Other Operating Expenses, Total 28656 -2385 26186 47179 22704
Operating Income 168571 88562 146990 104438 150515
Interest Income (Expense), Net Non-Operating -33538 -40647 -39837 -39890 4959
Net Income Before Taxes 135033 47915 107153 64549 155473
Net Income After Taxes 89406 31136 119149 61732 105021
Minority Interest -11 -2 -22 10 -7
Net Income Before Extra. Items 89395 31134 119127 61742 105014
Net Income 89395 31134 119127 61742 105014
Income Available to Common Excl. Extra. Items 89395 31134 119127 61742 105014
Income Available to Common Incl. Extra. Items 89395 31134 119127 61742 105014
Diluted Net Income 89395 31134 119127 61742 105014
Diluted Weighted Average Shares 1565.04 1583.78 1570.42 1563.73 1545.71
Diluted EPS Excluding Extraordinary Items 57.1199 19.658 75.857 39.4837 67.9392
Dividends per Share - Common Stock Primary Issue 0 90 0 90 0
Diluted Normalized EPS 57.1199 24.2709 82.0233 39.4837 67.9392
Total Adjustments to Net Income 0
Other, Net 1 -1
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total Current Assets 2397960 2593640 2712890 2469430 2993040
Cash and Short Term Investments 553704 875000 1002820 653436 725819
Cash & Equivalents 533530 389058 335027 188640 462890
Short Term Investments 20174 485942 667793 464796 262929
Total Receivables, Net 681693 724377 812714 784921 749119
Accounts Receivable - Trade, Net 649429 617517 707487 670708 657681
Total Inventory 986457 853167 753881 759599 919670
Other Current Assets, Total 176102 141098 143478 271476 598429
Total Assets 13957800 13178000 12912300 12821100 13792800
Property/Plant/Equipment, Total - Net 1691230 1582800 1453920 1386370 1331930
Property/Plant/Equipment, Total - Gross 2453010 2191740 2084120 1971520
Accumulated Depreciation, Total -870208 -737818 -697754 -639591
Goodwill, Net 4790720 4407750 4033920 4012530 4240250
Intangibles, Net 4269660 3818540 3909110 4171360 4751170
Long Term Investments 378857 330133 348350 369455 299922
Other Long Term Assets, Total 429328 445150 454110 411948 176463
Total Current Liabilities 2481940 2145730 1773180 2175900 2553050
Accounts Payable 649233 295933 232105 211627 212348
Notes Payable/Short Term Debt 285 69 5014 500002
Current Port. of LT Debt/Capital Leases 339600 203708 22084 581803 484944
Other Current Liabilities, Total 1493110 1645800 1518920 1377450 1355760
Total Liabilities 7603630 7495000 7739260 8097610 8610790
Total Long Term Debt 4042740 4141420 4613220 4506490 4766000
Long Term Debt 4042740 4141420 4613220 4506490 4766000
Deferred Income Tax 295178 473145 576542 765079 783356
Minority Interest 549 504 4140 4003 4006
Other Liabilities, Total 783219 734202 772180 646144 504372
Total Equity 6354120 5683020 5173040 4723480 5181980
Common Stock 1676340 1676260 1668140 1668120 1643580
Additional Paid-In Capital 1728830 1708870 1688420 1680290 1650230
Retained Earnings (Accumulated Deficit) 1541150 1479720 1509910 1369970 1595430
Treasury Stock - Common -100317 -116007 -59552 -87463 -57142
Unrealized Gain (Loss) 12470 22068 41983 22891 46380
Other Equity, Total 1495650 912106 324131 69673 303499
Total Liabilities & Shareholders’ Equity 13957800 13178000 12912300 12821100 13792800
Total Common Shares Outstanding 1554.53 1550.36 1563.36 1557.77 1554.78
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 2397960 2595950 2745620 2549520 2593640
Cash and Short Term Investments 553704 726608 830069 664534 875000
Cash & Equivalents 533530 685141 798137 645991 849695
Short Term Investments 20174 41467 31932 18543 25305
Total Receivables, Net 681693 779872 800536 794092 724377
Accounts Receivable - Trade, Net 649429 707318 759894 762126 696644
Total Inventory 986457 927286 953450 927511 853167
Other Current Assets, Total 176102 162180 161561 163378 141098
Total Assets 13957800 13504700 14588800 14065400 13178000
Property/Plant/Equipment, Total - Net 1691230 1656420 1760330 1705370 1582800
Goodwill, Net 4790720 4690950 4994630 4813610 4407750
Intangibles, Net 4269660 3765760 4187060 4145090 3818540
Long Term Investments 378857 369469 425766 381607 330133
Other Long Term Assets, Total 429328 426168 475451 470237 445150
Total Current Liabilities 2481940 2236810 2391720 2166940 2145730
Accounts Payable 649233 381109 388616 424358 516297
Notes Payable/Short Term Debt 0 0 0 285
Current Port. of LT Debt/Capital Leases 339600 372019 568228 281897 203708
Other Current Liabilities, Total 1493110 1483680 1434880 1460690 1425440
Total Liabilities 7603630 7328730 7875920 7748590 7495000
Total Long Term Debt 4042740 3914880 4168420 4320360 4141420
Long Term Debt 4042740 3914880 4168420 4320360 4141420
Deferred Income Tax 295178 413833 493229 483372 473145
Minority Interest 549 520 560 551 504
Other Liabilities, Total 783219 762681 821992 777372 734202
Total Equity 6354120 6175980 6712930 6316830 5683020
Common Stock 1676340 1676330 1676330 1676280 1676260
Additional Paid-In Capital 1728830 1712040 1695540 1707340 1708870
Retained Earnings (Accumulated Deficit) 1541150 1507720 1530200 1459760 1479720
Treasury Stock - Common -100317 -100314 -100313 -129184 -116007
Unrealized Gain (Loss) 13341 16819 17163 22068
Other Equity, Total 1508120 1366860 1894350 1585480 912106
Total Liabilities & Shareholders’ Equity 13957800 13504700 14588800 14065400 13178000
Total Common Shares Outstanding 1554.53 1554.52 1554.52 1546.1 1550.36
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Net income/Starting Line 317038 230166 376171 44290 109014
Cash From Operating Activities 977156 1123100 1010930 670381 328301
Cash From Operating Activities 664400 583151 559671 583649 272446
Non-Cash Items 327626 252109 12308 172928 39061
Cash Taxes Paid 185966 140423 201687 226768 44909
Cash Interest Paid 108555 108207 107350 127211 34914
Changes in Working Capital -331908 57679 62781 -130486 -92220
Cash From Investing Activities -607102 -198125 393530 292119 -2835700
Capital Expenditures -633689 -186037 -236468 -217710 -134114
Other Investing Cash Flow Items, Total 26587 -12088 629998 509829 -2701580
Cash From Financing Activities -709148 -1070260 -1088350 -1005210 2946240
Financing Cash Flow Items -117732 -108592 -142352 -132804 -71143
Total Cash Dividends Paid -279416 -283665 -283357 -282582 -142952
Issuance (Retirement) of Stock, Net -26929 -77531 -2141 -3737 -1172
Issuance (Retirement) of Debt, Net -285071 -600477 -660504 -586090 3161500
Foreign Exchange Effects 22929 28758 12501 -21766 -31269
Net Change in Cash -316165 -116527 328608 -64479 407571
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 317038 285903 166753 105021 230166
Cash From Operating Activities 977156 683463 305234 84241 1123100
Cash From Operating Activities 664400 502990 326110 158283 583151
Non-Cash Items 327626 218641 140497 51740 252109
Cash Taxes Paid 185966 165066 109217 20855 140423
Cash Interest Paid 108555 86563 52719 22770 108207
Changes in Working Capital -331908 -324071 -328126 -230803 57679
Cash From Investing Activities -607102 -168610 -121920 -94714 -198125
Capital Expenditures -633689 -189609 -138985 -98376 -186037
Other Investing Cash Flow Items, Total 26587 20999 17065 3662 -12088
Cash From Financing Activities -709148 -702548 -267593 -215717 -1070260
Financing Cash Flow Items -117732 -92527 -52761 -22786 -108592
Total Cash Dividends Paid -279416 -268997 -140007 -128873 -283665
Issuance (Retirement) of Stock, Net -26929 -26929 -26929 -26929 -77531
Issuance (Retirement) of Debt, Net -285071 -314095 -47896 -37129 -600477
Foreign Exchange Effects 22929 23141 32720 22485 28758
Net Change in Cash -316165 -164554 -51559 -203705 -116527

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Takeda Pharmaceutical Company Limited Company profile

About Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Financial summary

BRIEF: For the nine months ended 31 December 2021, Takeda Pharmaceutical Co Ltd revenues increased 11% to Y2.696T. Net income applicable to common stockholders increased 35% to Y241.42B. Revenues reflect Intellectual Property And Service Revenue segment increase from Y69.04B to Y210.55B, Pharmaceutical Business segment increase of 5% to Y2.485T, Northern America segment increase of 9% to Y1.297T, Japan segment increase of 22% to Y530.25B.

Equity composition

FY'94-02 WAS were estimated. FY'04 Name changed from Takeda Chemical Industries, Ltd. to Takeda Pharmaceutical Company Limited. All 1&3Q, WAS were estimated and used as O/S. FY'08 Q3 WAS=O/S. FY'11 Q3 DWAS is estimated.

Industry: Pharmaceuticals (NEC)

4階
日本橋本町二丁目1番1号
CHUO-KU
TOKYO-TO 103-8668
JP

Income Statement

  • Annual
  • Quarterly

News

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023

People also watch

Oil - Crude

90.08 Price
+0.720% 1D Chg, %
Long position overnight fee 0.0445%
Short position overnight fee -0.0664%
Overnight fee time 21:00 (UTC)
Spread 0.030

BTC/USD

26,202.40 Price
-0.420% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

XRP/USD

0.51 Price
+0.480% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

US100

14,554.20 Price
-1.450% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading